Evidence map›Paper›PMID 41709025›Full record

SynthesisEuropean journal of pediatrics2026

The role of microRNAs in Kawasaki disease: a systematic review.

Grzegorz Procyk, Natalia Rosół, Łukasz Lamparski, Wiktoria Modrzejewska, Zofia Wcisło, Julia Procyk, Aleksandra Gąsecka, Bożena Werner

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Grzegorz Procyk1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097, Warsaw, Poland. grzegorz.procyk@wum.edu.pl.
Natalia Rosół1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097, Warsaw, Poland.
Łukasz Lamparski1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097, Warsaw, Poland.
Wiktoria Modrzejewska1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097, Warsaw, Poland.
Zofia Wcisło1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097, Warsaw, Poland.
Julia ProcykUniversity Clinical Hospital in Wroclaw, Borowska 213, 50-556, Wroclaw, Poland.
Aleksandra Gąsecka1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-097, Warsaw, Poland.
Bożena WernerDepartment of Pediatric Cardiology and General Pediatrics, Medical University of Warsaw, 02-097, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kawasaki disease (KD) is an acute vasculitis affecting medium-sized vessels and characterized by fever lasting more than 5 days. Differential diagnosis of KD is challenging. Microribonucleic acids (miRNA/miR) have been widely studied as potential biomarkers for diagnosing KD. The objective of this study is to systematically review the clinical utility of miRNAs in KD. This systematic review followed the PRISMA 2020 guidelines. We included English-language, full-text observational studies enrolling adult and/or pediatric patients with KD (complete or incomplete) which quantified miRNA expression levels or genotyped single-nucleotide polymorphisms (SNPs) in miRNA genes. We searched the following databases: Embase, Medline Ultimate, PubMed, Scopus, and Web of Science. Each database was last searched on January 12, 2026. Thirty-six studies met the eligibility criteria and were included in this review. The most reproducible finding concerns miR-223 which has been repeatedly reported to be upregulated in KD patients compared with both healthy and febrile controls. Several miRNAs have been described to distinguish specific KD phenotypes, e.g., coronary artery lesion (CAL) formation and intravenous immunoglobulin (IVIG) responsiveness. The majority of investigated SNPs in miRNA genes were not associated with KD susceptibility; however, some associations were reported, including with KD phenotypes such as CAL formation.Conclusions: Multiple studies have shown dysregulation of miRNA expression in KD patients and the potential utility of miRNAs in diagnosing KD and identifying individuals at risk of CAL formation or IVIG resistance. Nevertheless, there is a need for methodological standardization in future research and for studies including multiethnic cohorts. What's Known? • No single test for Kawasaki Disease is available; it can be diagnosed in patients meeting the clinical criteria. • Microribonucleic acids are promising biomarkers in various cardiovascular conditions including Kawasaki Disease. What's New? • To the best of our knowledge, this is the first systematic review evaluating microribonucleic acids in Kawasaki Disease using PRISMA guidelines. • Studies regarding the role of microribonucleic acids in Kawasaki Disease are highly heterogeneous but several of them display significant potential as diagnostic biomarkers.

Indexed as

MicroRNAsMucocutaneous Lymph Node SyndromeBiomarkersHumansPolymorphism, Single NucleotideBiomarkersMicroRNAsBiomarkersKawasaki diseaseMicroRNAsSystematic reviewVasculopathy

Identifiers

PMID41709025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.